Heart failure (HF) is a major and increasing global public health problem. In Asia, aging populations and recent increases in cardiovascular risk factors have contributed to a particularly high burden of HF, with outcomes that are poorer than those in the rest of the world. Representation of Asians in landmark HF trials has been variable. In addition, HF patients from Asia demonstrate clinical differences from patients in other geographic regions. Thus, the generalizability of some clinical trial results to the Asian population remains uncertain. In this article, we review differences in HF phenotype, HF management, and outcomes in patients from East and Southeast Asia. We describe lessons learned in Asia from recent HF registries and clinical trial databases and outline strategies to improve the potential for success in future trials. This review is based on discussions among scientists, clinical trialists, industry representatives, and regulatory representatives at
H eart failure (HF) is a major public health problem worldwide (1, 2) . In Asia, aging populations and large increases in cardiovascular risk factors have contributed to a high burden of HF (3) . HF patients from Asia differ in clinical characteristics from patients elsewhere and yet have similarly poor or even worse outcomes than HF patients from the West ( Table 1 
BURDEN OF HF
Limited data are available regarding the true incidence and prevalence of HF in Asia (3). Studies of hospitalized patients in Singapore, Malaysia, and
Taiwan found that 3% to 7% of admissions were due to HF in the 1990s to early 2000s (10) (11) (12) . In a community-based survey, the prevalence of HF in
China among populations 55 to 74 years of age was 1.3%, with an estimated overall adult HF population >4 million (13). Similarly, in Japan, it is estimated that 1 million people have HF (14) , which equates to a prevalence of w1%. For instance, in the ATTEND registry (Acute decompensated heart failure syndromes) consisting of 4,841 acute HF patients enrolled in Japan, 31% of patients had ischemic, 19% had valvular, 18% had hypertensive, and 32% with "other/unspecified" causes (20) .
A chronic HF registry of 1,078 Japanese patients Mentz et al.
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ACEI ¼ angiotensin-converting enzyme inhibitor; AHF ¼ acute heart failure; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index; BNP ¼ brain natriuretic peptide; CRT ¼ cardiac resynchronization therapy; GFR ¼ glomerular filtration rate; HR ¼ heart rate; ICD ¼ implantable cardioverter-defibrillator; IV ¼ intravenous; LVEF ¼ left ventricular ejection fraction; MRA ¼ mineralocorticoid receptor antagonist; pEF ¼ preserved ejection fraction; rEF ¼ reduced ejection fraction; SBP ¼ systolic blood pressure.
reported that ischemia was the underlying cause in 26% of cases (19). These observations are notable given the high prevalence of CAD risk factors, including >40% of the Asian population with a smoking history and 45% with diabetes. Younger age may partially explain the discordance between risk factor burden and ischemic prevalence. Recent data suggest that ischemia-driven HF is increasing in Asia.
For instance, in Japan, the prevalence of CAD increased from 26% to 47% from 2000 to 2010 (19). ACE/ARB ¼ angiotensin-converting enzyme/angiotensin receptor blocker; AHF ¼ acute heart failure; CRT ¼ cardiac resynchronization therapy; disease, lung disease, and diabetes (21) . The recent increase in AF incidence in Asia is markedly higher than in North America/Europe (23, 24) , suggesting that AF may play an even more critical role in HF in Asia in the future (25) . Importantly, these observations may also be related to increased disease ascertainment in Asia.
Similarly, diabetes in Asia has increased in recent years due to changes in lifestyle involving physical inactivity and diet changes (26) . For instance, in Malaysia, obesity increased from 12% to 15% and diabetes increased from 12% to 15% from 2003 to 2011 (27) Mentz et al.
Heart Failure in Asia
Asian populations affect beta-blocker concentrations and clearance (42) . Given the small sample size of previous studies and the relative paucity of data pertaining to differences in pharmacological response in Asians (43) 
OUTCOMES
Regional differences in HF outcomes have been described (33, (52) (53) (54) . In ADHERE-AP, the median hospital length of stay (LOS) for HF was 6 days, and in-hospital mortality was 4.8% compared with 4 days and 4.0%, respectively, in ADHERE. This may be attributed, in part, to the ADHERE-AP cohort having an increased severity of disease due to larger enrollment from tertiary hospitals. In the Japanese ATTEND registry, median LOS was 21 days, and in-hospital mortality was 6.4% (20) . Japanese patients often Processes for ethics approval and requirements for regulatory approval also vary widely and must be taken into consideration for optimal design of trials in Asia.
